12 results about "Heart output" patented technology

The present disclosure provides a fully integrated autonomous wearable ultrasound patch system (USoP) that includes a miniaturized flexible control circuit designed to interface with an array of ultrasound transducers for signal pre-processing and wireless data communication. Artificial intelligence (e.g., machine learning) may be used to track mobile organization targets and assist in data interpretation. In one implementation, USoP allows continuous tracking of physiological signals from tissue up to 164 mm deep. For moving subjects, USoP may continuously monitor physiological signals, including central blood pressure, heart rate, and cardiac output, for example for 12 hours. This result enables continuous autonomous monitoring of deep tissue signals.

According to the cardiac output measurement device according to the present disclosure, it is possible to measure the cardiac output more easily in a non-invasive manner by calculating the cardiac output based on the first ultrasound reception signal and the second ultrasound reception signal received from the first ultrasound probe and the second ultrasound probe that are located in both directions based on the heart.

The invention provides a non-invasive cardiac expulsion measuring method and system. The method comprises the following steps: inputting preprocessed arterial pressure waveform signals and basic vital sign data into a parameter estimation neural network for feature extraction, and outputting a correction factor cal, a scale factor SF and a waveform correction coefficient; respectively inputting the correction factor cal, the scale factor SF and the waveform correction coefficient into a pulse contour model, a LiDCO power model and a FloTrac standard deviation model for calculation to obtain a cardiac output estimated value CO1, a cardiac output estimated value CO2 and a cardiac output estimated value CO3; and fusing the cardiac output estimated value CO1, the cardiac output estimated value CO2 and the cardiac output estimated value CO3 by adopting a gradient lifting regression tree model, and outputting a final cardiac output value. According to the invention, calibration-free continuous monitoring is realized, and the stability and precision of cardiac output estimation are improved.

The application discloses a diving decompression sickness dynamic prediction and risk assessment system of multi-tissue parallel computation, relates to the fields of diving medicine, high-pressure medicine and human physiology modeling, and comprises a tissue unit planning module, a central blood circulation and coupling module and a model calculation and risk assessment module. The system divides a human body into a plurality of core physiological tissue units, and plans each tissue unit as a hybrid model composed of three sub-units of "fast-middle-slow". Then, the system simulates a human circulatory system by defining cardiac output, arterial blood inert gas partial pressure and dynamically distributing blood flow according to the tissue type, so as to construct a simulation model. Finally, according to the environmental pressure-time profile corresponding to a diving plan and the breathing gas composition, the simulation model is used to parallelly calculate the inert gas tension of all tissue units and sub-units, so as to be used for dynamic prediction and risk assessment of decompression sickness. The application provides a higher safety margin for saturation diving and repeated diving.

Compositions for improving metabolic function in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. S-beta-hydroxybutyrate in pure or enriched form provides energy to the heart, dilates the arteries, decreases blood pressure and systemic vascular resistance, and increases cardiac output. S-Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. S-Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and provide one or more electrolytes. S-Beta-hydroxybutyrate esters provide more controlled release without adding electrolytes. Compositions for improving heart function in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.5% to 0% by enantiomeric equivalents of R-beta-hydroxybutyrate.

1. Name of the product in this design: Graphical User Interface for Perioperative Monitoring Data Acquisition and Display of Electronic Equipment. 2. Intended use of this design: for use in an electronic device. 3. The key design features of this product are the graphical user interface displayed in the electronic device. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The display screen panel adopts the conventional design, omitting the rear view, left view, right view, top view, and bottom view. 6. Purpose of the graphical user interface: This product design is used for monitoring data collection during the surgical period. 7. Human-computer interaction method of graphical user interface: The main view is the first interface; clicking "Data Hero" in the main view displays the change state diagram 1; clicking "OK" in the change state diagram 1 displays the change state diagram 2; clicking "Data Analysis" in the change state diagram 2 displays the change state diagram 3; clicking "Large View" at the bottom of the change state diagram 3 displays the change state diagram 4; clicking "Multi-parameter Time Series Plot" on the right side of the change state diagram 4 displays the change state diagram 5; clicking "Heart Rate-Systolic Blood Pressure Correlation Analysis" on the right side of the change state diagram 5 displays the change state diagram 6; clicking "HRV Analysis" on the right side of the change state diagram 6 displays the change state diagram 7; clicking "Cardiac Output-Mean Pressure Correlation Analysis" on the right side of the change state diagram 7 displays the change state diagram 8; clicking "AUC Analysis" on the right side of the change state diagram 8 displays the change state diagram 9; clicking "Event Log" at the bottom of the change state diagram 9 displays the change state diagram 9. Clicking "Record" displays status diagram 10; clicking "Collapse Drawer" at the top of status diagram 10 displays status diagram 11; clicking the gear icon in the lower left corner of status diagram 11 displays status diagram 12; clicking "Equipment Sorting" on the left side of status diagram 12 displays status diagram 13; clicking "Equipment Parameter Source" on the left side of status diagram 13 displays status diagram 14; clicking the head icon in the upper left corner of status diagram 14 displays status diagram 15; clicking "Pulse Oxygen Saturation Monitoring" in status diagram 15 displays status diagram 16; clicking "COHb" on the right side of status diagram 16 displays status diagram 17; clicking the red square stop button above status diagram 17 displays status diagram 18; clicking "OK" below status diagram 18 displays status diagram 19; scrolling down from status diagram 19 displays status diagram 20.

The utility model relates to the field of walking tests, in particular to a footpath mark monitoring device for a six-minute walking test, which comprises a test footpath and a movable guide rail, distance marks are arranged on the surface of the test footpath, the movable guide rail is arranged on one side of the test footpath, and a mark area is arranged on the other side of the test footpath. A moving seat is arranged at the upper end of the movable guide rail, guide sliding seats are fixedly mounted on the two sides of the lower end face of the moving seat and slidably connected with the upper end of the movable guide rail, and moving wheels are arranged on the two sides of the driving box; the non-invasive cardiac output monitor is additionally arranged, so that the motion state of a patient is synchronously recorded, hemodynamic parameters of the human body are continuously monitored in real time, the change of central functions in the resting, moving and motion processes is evaluated from the angle of hemodynamics, the test effect is improved, the movable guide rail is used for guiding, the movable seat synchronously follows to move, and the test efficiency is improved. And when the patient moves, the noninvasive cardiac output monitor is driven to move synchronously, so that the use of the monitor is facilitated.

The utility model discloses an ultrasound-based cardiac output measurement module and medical monitoring equipment, and the cardiac output measurement module comprises a module shell detachably connected to host equipment and a circuit board assembly arranged in the module shell, an ultrasonic probe interface and a signal transmission interface which are in communication connection with the circuit board assembly are embedded in the module shell, the ultrasonic probe interface is used for being connected with an ultrasonic probe, and the signal transmission interface is used for being in communication connection with a main processor in host equipment. The circuit board assembly comprises a parameter board used for controlling the ultrasonic probe to emit ultrasonic signals and obtaining cardiac output information according to returned ultrasonic echo signals. The cardiac output measurement module based on the ultrasound is inserted into the external installation space of the host shell in the form of an accessory module for use, the cardiac output measurement module based on the ultrasound is small in size, convenient to take and capable of being flexibly transferred, the whole equipment does not need to be pushed in the transferring process, and use is more convenient.

A cardiovascular monitoring system for measuring at least cardiac output comprises an implantable unit (2) configured for placement in a section of artery of a patient and a portable external unit (1) configured for mounting against or close to a patient's skin for bidirectional communication with the implantable unit. A cross-sectional area measurement sensor (8) includes at least one elastic conductive loop (15, 15a, 15b) and an electronic circuit (16) connected to the conductive loop configured to measure an inductance value of the conductive loop. At least one ultrasound transducer (7,11) is further configured to measure a velocity of blood flow based on a Doppler effect.

The invention provides a continuous cardiac output prediction method and system based on transfer learning. The method comprises the following steps: constructing a CCO prediction network model based on transfer learning; a two-stage transfer learning strategy is adopted to train a model, TCO (Intermittent Time Correction) regression transition is conducted to CCO monitoring, basic physiological parameters, MAP waveform features, depth time sequence features and individual specificity features are integrated, long-time dependence and local mutation features are captured through a TCN network, and the CCO monitoring accuracy is improved. The attention weighted fusion strategy dynamically optimizes the feature contribution, so that the model can comprehensively learn the hemodynamic law, the predicted Pearson's correlation coefficient R is greater than or equal to 0.96, and the percentage error PE is less than or equal to 12%; according to the method, a domain adaptive loss function is introduced to effectively reduce the domain difference between a public data set and a private data set, and smooth transition from intermittent prediction to continuous prediction is ensured by capturing a sequential relationship.

Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions.In one exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle.In another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI.In still another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output.In yet another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is about 6 years of age or older, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO2; (d) work rate at VAT; (e) VE / VCO2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.

1. The name of the design product: non-invasive cardiac output monitor. 2. The use of the design product: for non-invasive monitoring of human cardiac output. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.